Your session is about to expire
← Back to Search
Colchicine 0.6 mg for Atrial Fibrillation
Study Summary
This trial will study whether colchicine, a potent anti-inflammatory drug, can help improve patient outcomes after catheter ablation for atrial fibrillation.
- Atrial Fibrillation
- Recurrence
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 100 Patients • NCT01985425Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the main goals that we are hoping to achieve with this experiment?
"The primary outcome of this study will be compliance with treatment, as assessed over a 24-month period (with an estimated 18-month enrollment phase). Secondary outcomes include the rate of signs and symptoms of pericarditis (defined as evidence of new or worsening pericardial effusion on echocardiogram, friction rub on auscultation, or pleuritic chest pain), recurrence of atrial fibrillation within 2 weeks after catheter ablation (defined as any episode of atrial fibrillation lasting more than 30 seconds within 2 weeks after ablation for atrial fibrillation, at"
Why is Colchicine 0.6 mg often prescribed?
"gout flares is commonly treated with Colchicine 0.6 mg. Other conditions that can be treated by Colchicine 0.6 mg include behcet's syndrome, postcommissurotomy syndrome, and familial mediterranean fever."
Can people still sign up for this research program?
"This clinical trial, which is currently recruiting patients, was originally posted on 1/14/2020 and was last updated on 9/19/2022."
Just curious, how many people have signed up for this healthcare experiment?
"That is correct, the online information does show that the trial is open for recruitment. The listing was first posted on January 14th, 2020 and was most recently updated on September 19th, 2022. They are looking for a total of 200 people to participate at 1 site."
What have been the most serious adverse effects of Colchicine 0.6 mg in clinical trials?
"Colchicine 0.6 mg is a Phase 3 trial drug, meaning that there is some efficacy data as well as multiple rounds of safety data, so we feel confident giving it a score of 3."
Share this study with friends
Copy Link
Messenger